Albumin-bound Paclitaxel and Carboplatin Versus Epirubicin and Docetaxel for Triple-negative Breast Cancer

Abroad (travel likely)RecruitingPHASE4

Conditions

Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Cancer Hospital Affiliated to Harbin Medical University, Harbin, Heilongjiang, China
Contact: Study coordinator (Xuesong Chen) · cxs1978@163.com · +8615804500816
Contact: Principal Investigator (Xuesong Chen)
The Second Hospital of Jilin University, Changchun, Jilin, China
Contact: Study coordinator (Yingchao Zhang) · zhang_yc@jlu.edu.cn
Contact: Principal Investigator (Yingchao Zhang)
Dalian Municipal Central Hospital, Dalian, Liaoning, China
Contact: Study coordinator (Wenbin Guo) · drguowb@hotmail.com · +8613079850586
Contact: Principal Investigator (Wenbin Guo)
Panjin Liaohe Oilfield Gem Flower Hospital, Panjin, Liaoning, China
Contact: Study coordinator (Hongbin Han) · rose_030201@163.com · +8613704236001
Contact: Principal Investigator (Hongbin Han)
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
Contact: Study coordinator (Caigang Liu) · liucg@sj-hospital.org · +86 18940254967
Contact: Study coordinator (Rong Wu) · wur@sj-hospital.com · +86 18940251156
Contact: Principal Investigator (Caigang Liu)
Contact: Principal Investigator (Rong Wu)
The Fourth Affiliated Hospital of China Medical University, Shenyang, Liaoning, China
Contact: Study coordinator (Wei Tu) · cmu4htw@126.com · +8618900913000
Contact: Principal Investigator (Wei Tu)
Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, China
Contact: Study coordinator (Hong Xu) · xh4015@163.com · +8618900917779
Contact: Principal Investigator (Hong Xu)

Study leads

Caigang Liu, M.D., Ph.D.
Principal Investigator
Shengjing Hospital

View source on ClinicalTrials.gov Contact study team (email)